Clinical Trial

A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of the study is to evaluate safety, pharmacokinetics and efficacy of AB-106 monotherapy in the treatment of advanced NSCLC.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2020-05-19; most recent amendment 2026-02-04.
Status change: Recruiting → Active, Not Recruiting 2023-10-26
Status change: Not Yet Recruiting → Recruiting 2021-02-01
Trial Details
NCT Number NCT04395677
Lead Sponsor Nuvation Bio Inc.
Conditions Non Small Cell Lung Cancer
Enrollment 173 participants
Start Date 2020-07-07
Primary Completion 2024-06-07 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-02-06